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Identification of six new susceptibility loci for invasive epithelial 
ovarian cancer
A full list of authors and affiliations appears at the end of the article.
Genome-wide association studies (GWAS) have identified 12 epithelial ovarian cancer 
(EOC) susceptibility alleles. The pattern of association at these loci is consistent in BRCA1 
and BRCA2 mutation carriers who are at high EOC risk. After imputation to the 1000 
Genomes Project data, we assessed associations of 11 million genetic variants with EOC 
risk from 15,397 cases unselected for family history and 30,816 controls, 15,252 BRCA1 
mutation carriers and 8,211 BRCA2 mutation carriers (3,096 with ovarian cancer), and 
combined the results in a meta-analysis. This new study design yielded increased statistical 
power, leading to the discovery of six new EOC susceptibility loci. Variants at 1p36 (nearest 
gene WNT4), 4q26 (SYNPO2), 9q34.2 (ABO) and 17q11.2 (ATAD5) were associated with 
EOC risk, and at 1p34.3 (RSPO1) and 6p22.1 (GPX6) specifically with the serous EOC 
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subtype, at p<5×10−8. Incorporating these variants into risk assessment tools will improve 
clinical risk predictions for BRCA1/2 mutation carriers.
The risk of developing invasive EOC is higher than the population average for relatives of 
women diagnosed with the disease1,2, indicating the importance of genetic factors in disease 
susceptibility. Approximately 25% of the familial aggregation of EOC is explained by rare, 
high-penetrance alleles of BRCA1 and BRCA23. Furthermore, population-based GWAS have 
identified common variants associated with invasive EOC at 11 loci4–9 but only six have 
also been evaluated in BRCA1 and/or BRCA2 mutation carriers. All loci displayed 
associations in mutation carriers that were consistent with the associations observed in the 
general population10–12. In addition, the 4q32.3 locus is associated with EOC risk for 
BRCA1 mutation carriers only13. However, the common genetic variants explain less than 
3.1% of the excess familial risk of EOC so additional susceptibility loci are likely to exist.
Women diagnosed with EOC and unaffected women from the general population 
ascertained through the Ovarian Cancer Association Consortium (OCAC)14 and BRCA1 and 
BRCA2 mutation carriers from the Consortium of Investigators of Modifiers of BRCA1/2 
(CIMBA)15 were genotyped as part of the Collaborative Oncological Gene-environment 
Study (COGS) using the iCOGS custom array. In addition, data were available for cases and 
controls from three EOC GWAS. We first evaluated whether the EOC susceptibility loci at 
8q21.13, 10p12.31, 17q12, 5p15.33, and 17q21.31 recently identified by OCAC7–9 also 
show evidence of association in BRCA1 and BRCA2 mutation carriers. Using data from 
>200,000 genotyped SNPs7,13,16, we performed imputation of common variants from the 
1000 Genomes Project data17 and evaluated the associations of these SNPs with invasive 
EOC risk in OCAC and in BRCA1 and BRCA2 mutation carriers from CIMBA. Given the 
strong evidence for a significant overlap in loci predisposing to EOC in the general 
population and those associated with risk in BRCA1 and BRCA2 mutation carriers, we 
carried out a meta-analysis of the EOC risk associations in order to identify novel EOC 
susceptibility loci.
Genotype data were available for imputation on 15,252 BRCA1 mutation carriers and 8,211 
BRCA2 mutation carriers, of whom 2,462 and 631, respectively, were affected with 
EOC13,16. From OCAC, genotyping data were available from 15,437 women with invasive 
EOC (including 9,627 with serous EOC) and 30,845 controls from the general population7. 
Imputation was performed separately for BRCA1 carriers, BRCA2 carriers, OCAC-COGS 
samples and the three OCAC GWAS (Supplementary Tables 1–2; Supplementary Fig. 1; 
Supplementary Fig. 2). The meta-analysis was based on 11,403,952 SNPs (Supplementary 
Fig. 3).
Of five EOC susceptibility loci that have not yet been evaluated in mutation carriers, two 
were associated with EOC risk for both BRCA1 and BRCA2 mutation carriers at p<0.05 
(10p12.31 and 17q21.31) (Supplementary Table 3). Overall, seven of the twelve known 
EOC susceptibility loci provided evidence of association in BRCA1 mutation carriers and six 
were associated in BRCA2 mutation carriers. However, with the exception of 5p15.33 
(TERT), all loci had hazard ratio (HR) estimates in BRCA1 and BRCA2 carriers that were in 
the same direction as the odds ratio (OR) estimates for serous subtype EOC from OCAC 
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(Fig. 1). Analysing the associations jointly in BRCA1 and BRCA2 carriers and serous EOC 
in OCAC provided stronger evidence of association, with smaller p-values for eight of the 
susceptibility variants compared to the analysis in OCAC alone.
Using the imputed genotypes, we observed no novel associations at p<5×10−8 in the analysis 
of associations in BRCA1 or BRCA2 mutation carriers separately. However, we identified 
seven previously unreported associations (p-values<5×10−8) in either OCAC alone, the 
meta-analysis of EOC associations in BRCA1, BRCA2 carriers and OCAC, or in the meta-
analysis in BRCA1 and BRCA2 carriers and serous EOC in OCAC (Supplementary Fig. 4; 
Supplementary Tables 4–5). SNPs in six of these loci remained genome-wide statistically 
significant after re-imputing genotypes with imputation parameters set to maximise accuracy 
(Table 1; Fig. 1). SNPs at 17q11.2 (near ATAD5) were found to be associated with invasive 
EOC in OCAC (p<5×10−8) (Table 1). For the lead SNP, chr17:29181220:I, the estimated 
HR estimate for BRCA1 mutation carriers was significantly different from the estimate in 
OCAC (p=0.005); the association for BRCA2 carriers was consistent with the OCAC OR 
estimate (BRCA2-OCAC meta-analysis p=2.6×10−9). SNPs at four loci were associated at 
p<5×10−8 with risk of all invasive EOC in the meta-analysis (Supplementary Fig. 5): 1p36, 
1p34.3, 4q26, and 9q34.2. At 1p34.3, the most strongly associated SNP, rs58722170, 
displayed stronger associations in the meta-analysis of serous EOC for OCAC 
(p=2.7×10−12). In addition, SNPs at 6p22.1 were associated at genome-wide significance 
level in the meta-analysis of associations with serous EOC (p=3.0×10−8), but not in the 
meta-analysis of all invasive EOC associations (p=6.8×10−6).
The most significantly associated SNP at each of the six novel loci had high imputation 
accuracy (r2≥0.83). At the 1p34.3, 1p36, and 6p22.1 loci, there was at least one genome-
wide significant genotyped SNP correlated with the lead SNP (pairwise r2≥0.73) 
(Supplementary Table 6; Supplementary Fig. 5; Supplementary Note). We genotyped the 
leading (imputed) SNPs of the three other loci in a subset of the samples using iPLEX 
(Supplementary Note). The correlations between the expected allele dosages from the 
imputation and the observed genotypes for the variants at 4q26 and 9q34.2, (r2=0.90 and 
r2=0.84, respectively) were consistent with the estimated imputation accuracy (0.93 and 0.83 
for CIMBA samples). The lead SNP at 17q11.2 failed iPLEX design. However, the risk 
allele is highly correlated with the AA haplotype of two genotyped variants on the iCOGS 
array (rs9910051 and rs3764419). This haplotype is strongly associated with ovarian cancer 
risk in the subset of samples genotyped using iCOGS (BRCA2-OCAC meta-analysis 
p=8.6×10−8 for haplotype, and p=1.8×10−8 for chr17:29181220:I) (Supplementary Table 7).
None of the regions contained additional SNPs that displayed EOC associations at p<10−4 in 
OCAC, BRCA1 carriers or BRCA2 carriers in multi-variable analyses adjusted for the lead 
SNP in each region, indicating that they each contain only one independent set of correlated 
highly associated variants (iCHAV). Relative to the 1000 Genomes Project data, we had 
genotyped or imputed data covering 91% of the genetic variation at 1p36, 84% at 1p34.3 
and 83% at 4q26. The other three novel loci had coverage of less than 80% (Supplementary 
Note). There was evidence for heterogeneity at p<0.05 in the associations with histological 
subtype in OCAC for the lead SNPs at 1p34.4 and 6p22.1, but not for at 1p36, 4q26, 9q34.2 
and 17q11.2 (Table 2).
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We carried out a competing risks association analysis in BRCA1 and BRCA2 mutation 
carriers in order to investigate whether these loci are also associated with breast cancer risk 
for mutation carriers (Supplementary Note). We used the most strongly associated 
genotyped SNPs for this purpose because the statistical method requires actual genotypes18. 
The EOC HR estimates were consistent with the estimates from the main analysis for all 
SNPs (Supplementary Table 8). None of the SNPs displayed associations with breast cancer 
risk at p<0.05.
At each of the six loci, we identified a set of SNPs with odds of less than 100 to 1 against 
being the causal variant; most are in non-coding DNA regions (Supplementary Table 9). 
None were predicted to have likely deleterious functional effects although some lie in or 
near chromatin biofeatures in fallopian tube and ovarian epithelial cells which may represent 
the functional regulatory targets of the risk SNPs (Table 3; Supplementary Table 10). We 
also evaluated the protein coding genes in each region for their role in EOC development, 
and as candidate susceptibility gene targets. Molecular profiling data from 496 HGSOCs 
performed by The Cancer Genome Atlas (TCGA) indicated frequent loss/deletion at four 
risk loci (1p36, 4q26, 9q34.2 and 17q11.2) (Supplementary Table 11). Consistent with this, 
WNT4 and ABO were significantly down-regulated in ovarian tumours while ATAD5 was 
up-regulated. Somatic coding sequence mutations in the six genes nearest the index SNPs 
were rare. We performed expression quantitative trait locus (eQTL) analysis in a series of 59 
normal ovarian tissues (Supplementary Table 12) to evaluate the gene nearest the top ranked 
SNP at each locus. For the five genes expressed in normal cells, we found no statistically 
significant eQTL associations for any of the putative causal SNPs at each locus; neither did 
we find any significant tumour-eQTL associations for these genes based on data from 
TCGA (Supplementary Table 12). At the 1p36 locus, the most strongly associated variant, 
rs56318008, is located in the promoter region of WNT4 which encodes a ligand in the WNT 
signal transduction pathway, critical for cell proliferation and differentiation. Using a 
luciferase reporter assay we found no effect of these putatively causal SNPs on WNT4 
transcription in iOSE4 normal ovarian cells (Fig. 2). Some of the putative causal SNPs at 
1p36 are located in CDC42 and LINC00339, and several are in putative regulatory domains 
in ovarian tissues (Supplementary Table 10; Fig. 2). CDC42 is known to play a role in 
migration and signalling in ovarian and breast cancer19,20. SNPs at 1p36 are also associated 
with increased risk of endometriosis and WNT4, CDC42 and LINC00339 have all been 
implicated in endometriosis21, a known risk factor for endometrioid and clear cell EOC22.
The strongest associated variant at 1q34, rs58722170, is located in RSPO1, which encodes 
R-spondin 1, a protein involved in cell proliferation (Supplementary Fig. 6). RSPO1 is 
important in tumorigenesis and early ovarian development23,24, and regulates WNT4 
expression in the ovaries25. SYNPO2 at 4q26 encodes myopodin which is involved in cell 
motility and growth26 and has a reported tumour suppressor role27–30. rs635634 is located 
upstream of the ABO gene (Supplementary Fig. 7). A moderately correlated variant 
(rs505922, r2=0.52) determines ABO blood group and is associated with increased risk of 
pancreatic cancer31,32. Previous studies in OCAC also showed a modestly increased risk of 
EOC for individuals with the A blood group33. The moderate correlation between rs635634 
and rs505922 and considerably weaker EOC association of rs505922 (p=1.2×10−5) suggests 
Kuchenbaecker et al. Page 4
Nat Genet. Author manuscript; available in PMC 2015 August 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
that the association with blood group is probably not driving the association with risk. The 
indel, 17:29181220:I, at 17q11.2 is located in ATAD5 which acts as a tumour suppressor 
gene34–36 (Supplementary Fig. 8). ATAD5 modulates the interaction between RAD9A and 
BCL2 in order to induce DNA damage related apoptosis. Finally, rs116133110, at 6p22.1, 
lies in GPX6 which has no known role in cancer.
The six novel loci reported in this study increase the number of genome-wide significant 
common variant loci so far identified for EOC to 18. Taken together, these explain 
approximately 3.9% of the excess familial relative risk of EOC in the general population, 
and account for approximately 5.2% of the EOC polygenic modifying variance in BRCA1 
mutation carriers and 9.3% in BRCA2 mutation carriers. The similarity in the magnitude of 
associations between BRCA1 and BRCA2 carriers and population-based studies suggests a 
general model of susceptibility whereby BRCA1 and BRCA2 mutations and common alleles 
interact multiplicatively on the relative risk scale for EOC37. This model predicts large 
differences in absolute EOC risk between individuals carrying many alleles and individuals 
carrying few risk alleles of EOC susceptibility loci for BRCA1 and BRCA2 mutation 
carriers13,16. Incorporating EOC susceptibility variants into risk assessment tools will 
improve risk prediction and may be particularly useful for BRCA1 and BRCA2 mutation 
carriers.
METHODS
Study populations
We obtained data on BRCA1 and BRCA2 mutation carriers through CIMBA. Eligibility in 
CIMBA is restricted to females 18 years or older with pathogenic mutations in BRCA1 or 
BRCA2. The majority of the participants were sampled through cancer genetics clinics15, 
including some related participants. Fifty-four studies from 27 countries contributed data. 
After quality control, data were available on 15,252 BRCA1 mutation carriers and 8,211 
BRCA2 mutation carriers, of whom 2,462 and 631, respectively, were affected with EOC 
(Supplementary Table 1).
Data were available for the stage 1 of three population-based EOC GWAS. These included 
2,165 cases and 2,564 controls from a GWAS from North America (“US GWAS”)39, 1,762 
cases and 6,118 controls from a UK-based GWAS (“UK GWAS”)6, and 441 cases and 441 
controls from the Mayo GWAS. Furthermore, 11,069 cases and 21,722 controls were 
genotyped using the iCOGS array (“OCAC-iCOGS” stage data). Overall, 43 studies from 11 
countries provided data on 15,347 women diagnosed with invasive epithelial EOC, 9,627 of 
whom were diagnosed with serous EOC, and 30,845 controls from the general population.
All subjects included in this analysis were of European descent and provided written 
informed consent as well as data and blood samples under ethically approved protocols. 
Further details of the OCAC and CIMBA study populations as well as the genotyping, 
quality control and statistical analyses have been described elsewhere7,13,16.
Genotype data
Genotyping and imputation details for each study are shown in Supplementary Table 1.
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Confirmatory genotyping of imputed SNPs
To evaluate the accuracy of the imputation of the SNPs we found to be associated with EOC 
risk, we genotyped rs17329882 (4q26) and rs635634 (9q34.2) in a subset of 3,541 subjects 
from CIMBA using Sequenon’s iPLEX technology. The lead SNP at 17q11.2, 
chr17:29181220:I failed iPLEX design. We performed quality control of the iPLEX data 
according to the CIMBA guidelines. After quality control, we used the imputation results to 
generate the expected allele dosage for each genotyped sample and computed the Pearson 
product-moment correlation coefficient between the expected allele dosage and the observed 
genotype. The squared correlation coefficient was compared to the imputation accuracy as 
estimated from the imputation.
Quality control of GWAS and iCOGS genotyping data
We carried out quality control separately for BRCA1 carriers, BRCA2 carriers, the three 
OCAC GWAS, and OCAC-iCOGS samples, but quality criteria were mostly consistent 
across studies. We excluded samples if they were not of European ancestry, if they had a 
genotyping call rate < 95%, low or high heterozygosity, if they were not female or had 
ambiguous sex, or were duplicates (cryptic or intended). In OCAC studies, one individual 
was excluded from each pair of samples found to be first-degree relatives and duplicate 
samples between the iCOGS stage and any of the GWAS were excluded from the iCOGS 
data. SNPs were excluded if they were monomorphic, had call rate<95%, showed evidence 
of deviation from Hardy-Weinberg equilibrium or had low concordance between duplicate 
pairs. For the Mayo GWAS and the UK GWAS, we also excluded rare SNPs (MAF<1% or 
allele count <5, respectively). We visually inspected genotype cluster plots for all SNPs with 
P<10−5 from each of the newly identified loci. We used the R GenABEL library version 
1.6.7 for quality control40.
Genotype data were available for analysis from iCOGS for 199,526 SNPs in OCAC-iCOGS, 
200,720 SNPs in BRCA1 mutation carriers, and 200,908 SNPs in BRCA2 mutation carriers. 
After QC, for the GWAS, data were available on 492,956 SNPs for the US GWAS, 543,529 
SNPs for the UK GWAS and 1,587,051 SNPs for the Mayo GWAS (Supplementary Table 
2).
Imputation
We performed imputation separately for BRCA1 carriers, BRCA2 carriers, OCAC-iCOGS 
samples and each of the OCAC GWAS. We imputed variants from the 1000 Genomes 
Project data using the v3 April 2012 release17 as the reference panel. For OCAC-iCOGS, the 
UK GWAS and the Mayo GWAS, imputation was based on the 1000 Genomes Project data 
with singleton sites removed. To improve computation efficiency we initially used a two-
step procedure, which involved pre-phasing in the first step and imputation of the phased 
data in the second. We carried out pre-phasing using the SHAPEIT software41. We used the 
IMPUTE version 2 software for the subsequent imputation42 for all studies with the 
exception of the US GWAS for which the MACH algorithm implemented in the minimac 
software version 2012.8.15, mach version 1.0.18 was used. To perform the imputation we 
divided the data into segments of approximately 5Mb each. We excluded SNPs from the 
association analysis if their imputation accuracy was r2<0.3 or their minor allele frequency 
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(MAF) was <0.005 in BRCA1 or BRCA2 carriers or if their accuracy was r2<0.25 in OCAC-
iCOGS, the UK GWAS, UK GWAS or Mayo GWAS.
We performed more accurate imputation for the regions around the novel EOC loci from the 
joint analysis of the data from BRCA1 and BRCA2 carriers and the general population (any 
SNP with P<5×10−8). The boundaries of these regions were set +/− 500kb from any 
significantly associated SNP in the region. As in the first run, the 1000 Genomes Project 
data v3 were used as the reference panel and the software IMPUTE2 was applied. However, 
for the second round of imputation, we imputed genotypes without pre-phasing in order to 
improve accuracy. To further increase the imputation accuracy we changed some of the 
default parameters in the imputation procedure. These included an increase of the MCMC 
iterations to 90 (out of which the first 15 were used as burn-in), an increase of the buffer 
region to 500kb and an increase of the number of haplotypes used as templates when 
phasing observed genotypes to 100. These changes were applied consistently for all data 
sets.
Statistical analyses
Association analyses in the unselected ovarian cancer cases and controls 
from OCAC—We evaluated the association between genotype and disease using logistic 
regression by estimating the associations with each additional copy of the minor allele (log-
additive models). The analysis was adjusted for study and for population substructure by 
including the eigenvectors of the first five ancestry specific principal components as 
covariates in the model. We used the same approach to evaluate the SNP associations with 
serous ovarian cancer after excluding all cases with any other or with unknown tumour 
subtype. For imputed SNPs we used expected dosages in the logistic regression model to 
estimate SNP effect sizes and p-values. We carried out analyses separately for OCAC-
iCOGS and the three GWAS and pooled thereafter using a fixed effects meta-analysis. We 
carried out the analysis of re-imputed genotypes of putative novel susceptibility loci jointly 
for the OCAC-iCOGS and GWAS samples. All results are based on the combined data from 
iCOGS and the three GWAS. We used custom written software for the analysis.
Associations in BRCA1 and BRCA2 mutation carriers from CIMBA—We carried 
out the ovarian cancer association analyses separately for BRCA1 and BRCA2 mutation 
carriers. The primary analysis was carried out within a survival analysis framework with 
time to ovarian cancer diagnosis as the endpoint. Mutation carriers were followed until the 
age of ovarian cancer diagnosis, or risk-reducing salpingo-oophorectomy (RRSO) or age at 
last observation. Breast cancer diagnosis was not considered as a censoring event. In order 
to account for the non-random sampling of BRCA1 and BRCA2 mutation carriers with 
respect to their disease status we conducted the analyses by modelling the retrospective 
likelihood of the observed genotypes conditional on the disease phenotype18. We assessed 
the associations between genotype and risk of ovarian cancer using the 1 degree of freedom 
score test statistic based on the retrospective likelihood18,43. To account for the non-
independence among related individuals in the sample, we used an adjusted version of the 
score test statistic, which uses a kinship adjusted variance of the score44. We evaluated 
associations between imputed genotypes and ovarian cancer risk using a version of the score 
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test as described above but with the posterior genotype probabilities replacing the genotypes. 
All analyses were stratified by the country of origin of the samples.
We carried out the retrospective likelihood analyses in CIMBA using custom written 
functions in Fortran and Python. The score test statistic was implemented in R version 
3.0.145.
We evaluated whether there is evidence for multiple independent association signals in the 
region around each newly identified locus by evaluating the associations of genetic variants 
in the region while adjusting for the SNP with the smallest meta-analysis p-value in the 
respective region. This was done separately for BRCA1 carriers, BRCA2 carriers and OCAC.
For one of the novel associations, it was not possible to confirm the imputation accuracy of 
the lead SNP chr17:29181220:I at 17q11.2 through genotyping. Therefore, we inferred two-
allele haplotypes for rs9910051 and rs3764419, highly correlated with the lead SNP 
(r2=0.95), using an in-house program. These variants were genotyped on the iCOGS array 
and therefore this analysis was restricted to 14,733 ovarian cancer cases and 9,165 controls 
from OCAC-COGS, and 8,185 BRCA2 mutation carriers that had available genotypes for 
both variants based on iCOGS. The association between the AA haplotype and risk was 
tested using logistic regression in OCAC and using Cox regression in BRCA2 mutation 
carriers.
Meta-analysis—We conducted a meta-analysis of the EOC associations in BRCA1, 
BRCA2 carriers and the general population for genotyped and imputed SNPs using an 
inverse variance approach assuming fixed effects. We combined the logarithm of the per-
allele hazard ratio estimate for the association with EOC risk in BRCA1 and BRCA2 
mutation carriers and the logarithm of the per-allele odds ratio estimate for the association 
with disease status in OCAC. For the associations in BRCA1 and BRCA2 carriers, we used 
the kinship adjusted variance estimator44 which allows for inclusion of related individuals in 
the analysis. We only used SNPs with results in OCAC and in at least one of the BRCA1 or 
the BRCA2 analyses. We carried out two separate meta-analyses, one for the associations 
with EOC in BRCA1 carriers, BRCA2 carriers and EOC in OCAC, irrespective of tumour 
histological subtype, and a second using only the associations with serous EOC in OCAC. 
The number of BRCA1 and BRCA2 samples with tumour histology information was too 
small to allow for subgroup analyses. However, previous studies have demonstrated that the 
majority of EOCs in BRCA1 and BRCA2 mutation carriers are high-grade serous49–53. Meta-
analyses were carried out using the software “metal”, 2011-03-25 release54.
Candidate causal SNPs in each susceptibility region—In order to identify a set of 
potentially causal variants we excluded SNPs with a likelihood of being causal of less than 
1:100, by comparing the likelihood of each SNP from the association analysis with the one 
of the most strongly associated SNP46. The remaining variants were then analysed using 
pupasuite 3.1 to identify potentially functional variants (Supplementary Table 9).
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Functional analysis
Expression quantitative trait locus (eQTL) analysis in normal OSE and FTSE 
cells—Early-passage primary normal ovarian surface epithelial cells (OSECs) and fallopian 
tube epithelial cells were harvested from disease-free ovaries and fallopian tubes. Normal 
ovarian epithelial cells were collected by brushing the surface of the ovary with a sterile 
cytobrush, and were cultured in NOSE-CM55. Fallopian tube epithelial cells were harvested 
by Pronase digestion as previously described56, plated onto collagen-coated plastics (Sigma) 
and cultured in DMEM/F12 (Sigma-Aldrich) supplemented with 2% Ultroser G (BioSepra) 
and 1× penicillin/streptomycin (Lonza). By the time of RNA harvesting, fallopian tube 
cultures tested consisted of PAX8 positive fallopian tube secretory epithelial cells 
(FTSECs), consistent with previous observations that ciliated epithelial cells from the 
fallopian tube do not proliferate in vitro.
For gene expression analysis, RNA was harvested from 59 early passage samples: 54 
OSECs and 5 FTSECs from cell cultures harvested at ~80% confluency using the QIAgen 
miRNAeasy kit with on-column DNase 1 digestion. 500ng RNA was reverse transcribed 
using the Superscript III kit (Life Technologies). We preamplified 10ng cDNA using the 
TaqMan® Preamp Mastermix; the resulting product was diluted 1:60 and used to quantify 
gene expression using the following TaqMan® gene expression probes: WNT4, 
Hs01573504_m1; RSPO1, Hs00543475_m1; SYNPO2, Hs00326493_m1; ATAD5, 
Hs00227495_m1 and GPX6, Hs00699698_m1. Four control genes were also included: 
ACTB, Hs00357333_g1; GAPDH, Hs02758991_g1; HMBS, Hs00609293_g1 and HPRT1 
Hs02800695_m1 (all Life Technologies). Assays were run on an ABI 7900HT Fast Real-
Time PCR system (Life Technologies).
Data Analysis: Expression levels for each gene were normalized to the average of all four 
control genes. Relative expression levels were calculated using the δδCt method. 
Genotyping was performed on the iCOGs chips, as described above. Where genotyping data 
were not available for the most risk-associated SNP, the next most significant SNP was 
used: rs3820282 at 1p36, rs12023270 at 1p34.3, rs752097 at 4q26, rs445870 at 6p22.1, 
rs505922 at 9q34.2 and rs3764419 at 17q11.2. Correlations between genotype and gene 
expression were calculated in ‘R’. Genotype specific gene expression in the normal tissue 
cell lines (eQTL analysis) was compared using the Jonckheere-Terpstra test. IData were 
normalized to the four control genes and we tested for eQTL associations, grouping OSECs 
and FTSECs together. Secondly, OSECs were analysed alone. eQTL analyses were 
performed using 3 genotype groups, or two groups (with the rare homozygote samples 
grouped together with the heterozygote samples).
eQTL analysis in primary ovarian tumours—eQTL analysis in primary tumours was 
based on the publicly available data available from The Cancer Genome Atlas (TCGA) 
project, which includes 489 primary high grade serous ovarian cancers. The methods have 
been described elsewhere57. Briefly, we determined the ancestry for each case based on the 
germ line genotype data using EIGENSTRAT software with 415 HapMap genotype profiles 
as a control set. Only populations of Northern and Western European ancestries were 
included. We first performed a cis-eQTL analyses using a method we described previously, 
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in which the association between 906,600 germline genotypes and the expression levels of 
mRNA or miRNA (located within 500Kb on either side of the variant) were evaluated using 
linear regression model with the effects of somatic copy number and CpG methylation being 
deducted (For miRNA expression, the effect of CpG methylation is not adjusted for since 
the data are not available). To adjust for multiple tests, we adjusted the test P values using 
Benjamini-Hochberg method. A significant association was defined by a false discovery rate 
(FDR) of less than 0.1.
Having established a genome-wide cis-eQTL associaitions in this series of tumours, we then 
evaluated cis-eQTL associations for the top risk associations between each of the six new 
loci and the gene in closest proximity to the risk SNP. For each risk locus, we retrieved the 
genotype of all SNPs in ovarian cancer cases based on the Affymetrix 6.0 array. Using these 
genotypes and the impute2 March 2012 1000 Genomes Phase I integrated variant 
cosmopolitan reference panel of 1,092 individuals (Haplotypes were phased via SHAPEIT), 
we imputed the genotypes of SNPs in the 1000 Genomes Project in the target regions for 
TCGA samples58. For each risk locus where data for the most risk-associated variant were 
not available, we retrieved the imputed variants tightly correlated with the most risk-
associated variant. We then tested for association between imputed SNPs and gene 
expression using the linear regression algorithm described above, where each imputed SNP 
was coded as an expected allele count. Again, significant associations are defined by a false 
discovery rate (FDR) of less than 0.1.
Regulatory profiling of normal ovarian cancer precursor tissues—We performed 
genome-wide formaldehyde assisted regulatory element (FAIRE) and ChIP seq with histone 
3 lysine 27 acetylation (H3K27ac) and histone 3 lysine 4 monomethylation (H3K4me) for 
two normal OSECs, two normal FTSECs and two HGSOC cell lines (UWB1.289 and 
CAOV3) [Shen et al. in preparation]. These datasets annotate epigenetic signatures of open 
chromatin, and collectively indicate transcriptional enhancer regions. We analysed the 
FAIRE-seq and ChIP-seq datasets and publically available genomic data on promoter and 
UTR domains, intron/exon boundaries, and positions of non-coding RNA transcripts to 
identify SNPs from the 100:1 likely causal set that align with biofeatures that may provide 
evidence of SNP functionality.
Candidate Gene Analysis Using Genome Wide Profiling of Primary Ovarian 
Cancers
Data Sets: The Cancer Genome Atlas (TCGA) Project and COSMIC Datasets
TCGA has performed extensive genomic analysis of tumours from a large number of tissue 
types including almost 500 high-grade serous ovarian tumours. These data include somatic 
mutations, DNA copy number, mRNA and miRNA expression and DNA methylation. 
COSMIC is the catalogue of somatic mutations in cancer that collates information on 
mutations in tumours from the published literature59. They have also identified The Cancer 
Gene Census, which is a list of genes known to be involved in cancer. Data are available on 
a large number of tissue types, including 2,809 epithelial ovarian tumours.
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Somatic coding sequence mutations: We analysed all genes for coding somatic sequence 
mutations generated from either whole exome or whole genome sequencing. In TCGA, 
whole exome sequencing data were available for 316 high-grade serous EOC cases. In 
addition, we determined whether mutations had been reported in COSMIC59 and whether 
the gene was a known cancer gene in the Sanger Cancer Gene Census.
mRNA expression in tumour and normal tissue: Normalized and gene expression values 
(Level 3) gene expression profiling data were obtain from the TCGA data portal for three 
different platforms (Agilent, Affymetrix HuEx and Affymetrix U133A). We analysed only 
the 489 primary serous ovarian tumour samples included in the final clustering analysis58 
and eight normal fallopian tube samples. The boxplot function in R was used to compare 
ovarian tumour samples to the fallopian tube for 91 coding genes with expression data on 
any platform within a 1MB region around the most significant SNP at the six loci. A 
difference in relative expression between EOC and normal tissue was carried out using the 
Wilcoxon rank-sum test.
DNA copy number analysis: Serous EOC samples for 481 tumours with log2 copy number 
data were analysed using the cBio portal for analysis of TCGA data60,61. For each gene in a 
region the classes of copy number; homozygous deletion, heterozygous loss, diploid, gain, 
and amplification were queried individually using the advanced onco query language (OQL) 
option. The frequency of gain and amplification were combined as “gain”, and homozygous 
deletion and heterozygous loss were combined as “loss”.
Analysis of copy number vs mRNA expression: Serous EOC samples for 316 complete 
tumours (those with CNA, mRNA and sequencing data) were analysed. Graphs were 
generated using the cBio portal for analysis of TCGA data and the setting were mRNA 
expression data Z-score (all genes) with the Z-score threshold of 2 (default setting) and 
putative copy number alterations (GISTIC). The Z-score is the number of standard 
deviations away from the mean of expression in the reference population. GISTIC is an 
algorithm that attempts to identify significantly altered regions of amplification or deletion 
across sets of patients.
Luciferase Reporter Assay—The putative causal SNPs at the 1p36 locus lie in the 
WNT4 promoter and so we tested their effect on transcription in a luciferase reporter assay 
(Fig. 2D). Wild-type and risk haplotype (comprising five correlated variants) sequences 
corresponding to the region bound by hg19 co-ordinates chr1:22469416-22470869 were 
generated by Custom Gene Synthesis (GenScript Corporation), and then sub-cloned into 
pGL3-basic (Promega). Equimolar amounts of luciferase constructs (800 ng) and pRL-TK 
Renilla (50 ng) were co-transfected into ~8 × 104 iOSE462 normal ovarian cells in triplicate 
wells of 24 well plates using LipoFectamine 2000 (Life Technologies). Independent 
transfections were repeated three times. The Dual-Glo Luciferase Assay kit (Promega) was 
used to assay luciferase activity 24 hours post transfection using a BioTek Synergy H4 plate 
reader. The iOSE-4 cell line (derived by K. Lawrenson) was maintained under standard 
conditions and routinely tested for Mycoplasma and short tandem repeat profiled.
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Figure 1. 
Hazard ratios for the association with EOC of 12 previously reported epithelial ovarian 
cancer susceptibility variants and the six novel susceptibility variants for OCAC, BRCA1 
mutation carriers and BRCA2 mutation carriers
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Figure 2. 
The 1p36 epithelial ovarian cancer susceptibility locus
A) The Manhattan plot depicts the strength of association between all imputed and 
genotyped SNPs across the region bound by hg19 co-ordinates chr1:21922893-22991643. 
The dotted line represents the genome-wide significance level 5×10−8. Additional tracks 
show genes and enhancers in ovary as described in Hnisz et al38. Positions of SNPs for 
which imputation r2<0.3 and/or minor allele frequency <0.005 are shown in the bottom track 
as ‘untyped’ SNPs.
B) The shaded iCHAV from (A) is shown depicting the genes and the location of the WNT4 
promoter construct as a red box. Red ticks show the positions of the putative causal variants 
following likelihood ratio testing. Signals from FAIRE-seq data derived from ovarian cells 
are represented by black marks, and the locations of predicted CDC42 enhancers38 as blue 
boxes. The positions of genotyped SNPs, and those that were neither genotyped nor well 
imputed (‘untyped’), are shown.
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C) Normalised luciferase reporter activity following triplicate transfections of wildtype and 
risk haplotype WNT4 promoter constructs in iOSE4 cells. Error bars represent standard error 
from three independent experiments.
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